THE AUTHORS RESPOND

por Guzauskas, Gregory F, Hansen, Ryan N
Publicado 2021

The long‐term impact and value of curative therapy for HIV: a modelling analysis

por Guzauskas, Gregory F., Hallett, Timothy B.
Publicado 2023

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients

por Guzauskas, Gregory F, Salzberg, Marc, Wang, Bruce CM
Publicado 2018

Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis

por Serbin, Michael A., Guzauskas, Gregory F., Veenstra, David L.
Publicado 2016

The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness...

por Fazioli, Katherine T., Rind, David M., Guzauskas, Gregory F., Hansen, Ryan N., Pearson, Steven D.
Publicado 2020

The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People’s Republic of China

por Shi, Qiang, Hu, Shanlian, Furnback, Wesley E, Guzauskas, Gregory F, Shen, Jiejing, Wang, Bruce CM
Publicado 2017

Risk–Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Ado...

por Guzauskas, Gregory F., Villa, Kathleen F., Vanhove, Geertrui F., Fisher, Vicki L., Veenstra, David L.
Publicado 2017

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes

por Guzauskas, Gregory F, Rind, David M, Fazioli, Katherine, Chapman, Richard H, Pearson, Steven D, Hansen, Ryan N
Publicado 2021

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma

por Spencer, Scott J, Guzauskas, Gregory F, FeLizzi, Federico, Launonen, Aino, Dawson, Keith, Veenstra, David L, Masaquel, Anthony
Publicado 2021

The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in China

por Wang, Bruce C. M., Liu, Dongdong, Furnback, Wesley E., Bifa, Fan, Dong, Peng, Xie, Li, Guzauskas, Gregory F., Zhang, Sali
Publicado 2016

The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy: A Summary from the Institute for Clinical and Economic Review’s California Technology Asse...

por Tice, Jeffrey A., Guzauskas, Gregory F., Hansen, Ryan N., Herron-Smith, Serina, Segel, Celia, Walsh, Judith M. E., Pearson, Steven D.
Publicado 2020

Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value

por Chen, Yixi, Guzauskas, Gregory F., Gu, Chengming, Wang, Bruce C. M., Furnback, Wesley E., Xie, Guotong, Dong, Peng, Garrison, Louis P.
Publicado 2016

The Authors Respond

por Carlson, Josh J., Guzauskas, Gregory F., Chapman, Richard H., Synnott, Patricia G., Liu, Shanshan, Russo, Elizabeth T., Pearson, Steven D., Brouwer, Elizabeth D., Ollendorf, Daniel A.
Publicado 2018

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States

por Carlson, Josh J., Guzauskas, Gregory F., Chapman, Richard H., Synnott, Patricia G., Liu, Shanshan, Russo, Elizabeth T., Pearson, Steven D., Brouwer, Elizabeth D., Ollendorf, Daniel A.
Publicado 2018

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study

por Carlson, Josh J., Kim, David D., Guzauskas, Gregory F., Bennette, Caroline S., Veenstra, David L., Basu, Anirban, Hendrix, Nathaniel, Hershman, Dawn L., Baker, Laurence, Ramsey, Scott D.
Publicado 2018

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States

por Guzauskas, Gregory F., Garbett, Shawn, Zhou, Zilu, Spencer, Scott J., Smith, Hadley S., Hao, Jing, Hassen, Dina, Snyder, Susan R., Graves, John A., Peterson, Josh F., Williams, Marc S., Veenstra, David L.
Publicado 2020